Related Experiment Video
Updated: Jan 6, 2026

Author Spotlight: Advancing Diabetes Research with Static Exercise Training in Mice
Published on: March 29, 2024
Interconnection between myasthenia gravis and type 2 diabetes: emerging role of metformin in modulating
Ahmed Salem Al-Dhahi1,2, Hayder M Al-Kuraishy3, Ali I Al-Gareeb4
1Consultant Neurology, Department of Neuroscience, King Fahad Specialist Hospital, Tabuk, Saudi Arabia.
Abstract:
Myasthenia gravis (MG) represents the commonest autoimmune disorder affecting the neuromuscular junction (NMJ). The pathophysiology of MG is mainly linked to the formation of IgG autoantibodies directed against acetylcholine receptors (AChRs) in the NMJ. Besides, type 2 diabetes (T2D) is observed as a conceivable risk factor for the development and progression of MG. Also, T2D is further related with late-onset MG than early-onset MG. Nevertheless, there are no differences in the levels of autoantibodies in T2D patients with MG compared to T2D patients without MG. It has been proposed that increasing the production of advanced glycation end-products (AGEs) proteins and the expression of receptor glycation end-products (RAGE) in early T2D provokes the autoimmunity in MG. Additionally; AGE/RAGE signaling is augmented and contributes in the progression of autoimmunity in MG. Nonetheless, the fundamental association between MG and T2D is not totally elucidated. Therefore, this review aims to discuss and explain the link between T2D and MG. Findings of the present review highlighted that metformin mitigates the pathogenesis of both T2D and MG by regulating of PI3K/AKT/mTOR/AMPK axis and enhancing autophagy.
More Related Videos
08:01Measurement of Insulin- and Contraction-Stimulated Glucose Uptake in Isolated and Incubated Mature Skeletal Muscle from Mice
Published on: May 16, 2021
08:47Live Images of GLUT4 Protein Trafficking in Mouse Primary Hypothalamic Neurons Using Deconvolution Microscopy
Published on: December 7, 2017
Related Concept Videos
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
PI3K/mTOR/AKT Signaling Pathway
Oral Hypoglycemic Agents: Biguanides and Glitazones
Diabetes Mellitus: Type 2 and Gestational
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...